Wegovy vs Zepbound: The Top Weight Loss Medications Compared

The two FDA-approved GLP-1 weight loss injections go head to head. Semaglutide versus tirzepatide — which delivers better results?

Take the Free Quiz

Free consultation · No commitment · Results in weeks

Patient
Patient
Patient
Patient
Patient
4.9/5

From 2,000+ patients · Wegovy vs Zepbound is already seeing results

Licensed Providers
FDA-Approved Medications
Free Shipping
HIPAA Compliant
Updated March 2026Medically reviewed by licensed providers

Wegovy vs Zepbound: both are FDA-approved GLP-1 medications for weight loss. Wegovy (semaglutide) and Zepbound (tirzepatide) differ in mechanism and clinical efficacy. Weight Method offers both from $297/month with virtual consultations and licensed providers.

Overview

Wegovy (semaglutide 2.4 mg, Novo Nordisk) and Zepbound (tirzepatide up to 15 mg, Eli Lilly) are the two premier FDA-approved medications for chronic weight management. Both are once-weekly injections that reduce appetite and caloric intake, but they differ in mechanism: Wegovy targets the GLP-1 receptor alone, while Zepbound activates both GLP-1 and GIP receptors. This is the most consequential comparison in the weight loss medication space, as both represent the cutting edge of pharmaceutical obesity treatment.

Key Fact

Wegovy (semaglutide 2.4mg) produced 15.8% average weight loss in STEP 1; Zepbound (tirzepatide 15mg) produced 22.5% in SURMOUNT-1. Wegovy also showed a 20% reduction in major cardiovascular events in the SELECT trial — cardiovascular data Zepbound does not yet have.

Source: STEP 1 (NEJM 2021); SURMOUNT-1 (NEJM 2022); SELECT Trial (NEJM 2023)

Wegovy

ManufacturerNovo Nordisk
Active Ingredientsemaglutide
FDA IndicationChronic weight management
FDA Approval2021
FormulationInjectable pen
FrequencyOnce weekly
Available Doses0.25mg, 0.5mg, 1mg, 1.7mg, 2.4mg
Avg. Weight Loss15-17%
Our Price$297/mo

Zepbound

ManufacturerEli Lilly
Active Ingredienttirzepatide
FDA IndicationChronic weight management
FDA Approval2023
FormulationInjectable pen
FrequencyOnce weekly
Available Doses2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg
Avg. Weight Loss20-25%
Our Price$349/mo

Key Differences

Clinical trial data gives Zepbound the edge in raw weight loss numbers. The SURMOUNT trials showed Zepbound producing 20-25% average body weight loss at the highest dose, compared to 15-17% with Wegovy in the STEP trials. However, Wegovy has a longer track record with more published cardiovascular outcome data — the SELECT trial demonstrated a 20% reduction in major cardiac events. Zepbound costs $349/mo through Weight Method versus $297/mo for Wegovy.

Verdict

Zepbound is the stronger choice for patients focused purely on maximizing weight loss, with the best clinical trial results of any weight management medication to date. Wegovy offers proven cardiovascular benefits beyond weight loss and a lower price point. Both are available through Weight Method — semaglutide at $297/mo and tirzepatide at $349/mo — and your provider can help determine the best fit.

Ready to Get Started?

Answer a few quick questions to see if you qualify for GLP-1 medication.

Check Eligibility

Your Treatment Options

Clinically proven GLP-1 medications at transparent prices

Starting at$297/mo
Semaglutide
Most PopularIn Stock

Semaglutide

Same active ingredient as Ozempic® & Wegovy®. Proven to reduce body weight by up to 15%.

  • Weekly injection
  • Gradual dose increase
  • Provider monitoring
  • Free shipping
Check Eligibility
Tirzepatide
In Stock

Tirzepatide

Same active ingredient as Mounjaro® & Zepbound®. Dual-action GLP-1/GIP for enhanced results.

  • Weekly injection
  • Dual hormone action
  • Provider monitoring
  • Free shipping
Check Eligibility

Frequently Asked Questions

Zepbound produces more weight loss on average. Clinical trials show 20-25% body weight reduction with Zepbound versus 15-17% with Wegovy. Individual results vary, but across all dose comparisons, tirzepatide (Zepbound) has outperformed semaglutide (Wegovy) for weight reduction.

Both medications have similar safety profiles with gastrointestinal side effects being most common (nausea, diarrhea, constipation). Wegovy currently has more long-term safety data and a completed cardiovascular outcomes trial (SELECT) showing heart health benefits. Zepbound's cardiovascular trial is ongoing.

Zepbound (tirzepatide) uses a newer dual-action mechanism and is manufactured by a different company (Eli Lilly vs Novo Nordisk). Through Weight Method, the difference is modest — $349/mo for tirzepatide versus $297/mo for semaglutide — both significantly below retail pharmacy prices.

Yes, switching between the two is possible under medical supervision. Your provider will start you at a low Zepbound dose (2.5 mg) and titrate up over several weeks, regardless of your previous Wegovy dose. The transition period may involve temporary return of side effects as your body adjusts to the new medication.

Both are FDA-approved for adults with a BMI of 30 or higher (obesity), or BMI of 27 or higher (overweight) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Weight Method's online assessment evaluates your eligibility based on these clinical criteria.

Ready to Get Started?

Take our 2-minute quiz to see if you qualify for GLP-1 treatment.

Start Quiz

Free consultation. No commitment.

Related Brand Pages

Wegovy HubWegovy Side EffectsWegovy ResultsWegovy DosingZepbound HubZepbound Side EffectsZepbound ResultsZepbound Dosing

More Comparisons

Ozempic vs WegovyMounjaro vs ZepboundRybelsus vs Oral-wegovyOzempic vs MounjaroOzempic vs ZepboundWegovy vs Mounjaro